Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH). It's designed to mimic the effects of naturally occurring GHRH, which stimulates the pituitary gland to release growth hormone.
Key research notes
- Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH).
- It's designed to mimic the effects of naturally occurring GHRH, which stimulates the pituitary gland to release growth hormone.
- Tesamorelin is mainly studied for its effects on GH regulation and associated metabolic pathways in experimental research models.
Tesamorelin is mainly studied for its effects on GH regulation and associated metabolic pathways in experimental research models. Growth hormone-releasing hormone (GHRH) is a peptide produced in the hypothalamus.
It plays a key role in: Stimulating growth hormone (GH) release from the pituitary gland involved in pathways related to protein and lipid metabolism Participates in cellular signaling processes linked to growth and recovery Plays a role in circadian regulation of GH release patterns in research settings Because native GHRH is rapidly broken down in the body, researchers have created more stable analogues like Tesamorelin to allow for extended study.
How Tesamorelin is Being Studied: Observed Effects on Growth Hormone Secretion Tesamorelin binds to GHRH receptors on the pituitary gland, triggering a natural increase in GH secretion. In lab settings, this has allowed researchers to examine the downstream effects of elevated GH, such as changes in lipid metabolism and muscle development.
Effects on Visceral Adipose Tissue One of the most studied effects of Tesamorelin is its ability to reduce visceral fat, particularly in specific research populations. In multiple trials, Tesamorelin has been associated with measurable decreases in abdominal fat without significant impact on subcutaneous fat.
Observed Effects on Glucose Pathways Unlike some GH-related peptides that may affect glucose metabolism, Tesamorelin has been observed in some models to preserve or have minimal impact on insulin sensitivity, making it a key subject in metabolic research.
References
- Metabolic effects of a growth hormone-releasing factor in patients with HIV.
- The New England Journal of Medicine, 363(8), 716-726.
- Effects of tesamorelin on visceral fat and metabolic parameters in HIV-infected patients.
- Journal of Clinical Endocrinology & Metabolism, 96(9), 2738-2745.
- Tesamorelin: a growth hormone-releasing factor analogue for management of HIV-associated lipodystrophy.
The statements made on this website have not been evaluated by the Food and Drug Administration, the products offered are not intended to diagnose, treat, cure, or prevent any disease, AssayGrade Peptides is not a compounding pharmacy or chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act, and all products are sold strictly for research purposes only and are not for human or animal consumption.